Lanean...
Dalpiciclib Extends Progression‐Free Survival in HR+/HER2– Advanced Breast Cancer
The phase III DAWNA‐1 trial met its primary endpoint of improved progression‐free survival with dalpiciclib added to fulvestrant in previously treated HR‐positive, HER2‐negative advanced breast cancer, signaling a new option for combination therapy with a CDK4/6 inhibitor and endocrine therapy....
Gorde:
| Argitaratua izan da: | Oncologist |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Inc.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262302/ https://ncbi.nlm.nih.gov/pubmed/34152061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13865 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|